nodes	percent_of_prediction	percent_of_DWPC	metapath
Raloxifene—ESR1—hematologic cancer	0.224	1	CbGaD
Raloxifene—AOX1—Mercaptopurine—hematologic cancer	0.085	0.196	CbGbCtD
Raloxifene—CYP2B6—Thiotepa—hematologic cancer	0.0298	0.0687	CbGbCtD
Raloxifene—AOX1—Methotrexate—hematologic cancer	0.0278	0.0641	CbGbCtD
Raloxifene—CYP19A1—Betamethasone—hematologic cancer	0.0277	0.0639	CbGbCtD
Raloxifene—CYP2B6—Ifosfamide—hematologic cancer	0.0169	0.039	CbGbCtD
Raloxifene—CYP2C8—Bortezomib—hematologic cancer	0.0167	0.0385	CbGbCtD
Raloxifene—CYP19A1—Dexamethasone—hematologic cancer	0.0161	0.0371	CbGbCtD
Raloxifene—CYP2B6—Nilotinib—hematologic cancer	0.0147	0.0338	CbGbCtD
Raloxifene—CYP2C8—Ifosfamide—hematologic cancer	0.0128	0.0295	CbGbCtD
Raloxifene—ESR2—ovarian follicle—hematologic cancer	0.0123	0.212	CbGeAlD
Raloxifene—CYP2C8—Nilotinib—hematologic cancer	0.0111	0.0256	CbGbCtD
Raloxifene—CYP3A4—Bexarotene—hematologic cancer	0.011	0.0255	CbGbCtD
Raloxifene—CYP3A4—Lomustine—hematologic cancer	0.0103	0.0237	CbGbCtD
Raloxifene—CYP3A4—Busulfan—hematologic cancer	0.0103	0.0237	CbGbCtD
Raloxifene—CYP2B6—Irinotecan—hematologic cancer	0.0101	0.0233	CbGbCtD
Raloxifene—CYP19A1—ovarian follicle—hematologic cancer	0.00972	0.167	CbGeAlD
Raloxifene—CYP3A4—Thiotepa—hematologic cancer	0.00916	0.0211	CbGbCtD
Raloxifene—ESR1—ovarian follicle—hematologic cancer	0.00845	0.145	CbGeAlD
Raloxifene—CYP2B6—Cisplatin—hematologic cancer	0.00822	0.019	CbGbCtD
Raloxifene—CYP3A4—Methoxsalen—hematologic cancer	0.00712	0.0164	CbGbCtD
Raloxifene—CYP3A4—Bortezomib—hematologic cancer	0.00677	0.0156	CbGbCtD
Raloxifene—CYP2B6—Dexamethasone—hematologic cancer	0.00664	0.0153	CbGbCtD
Raloxifene—CYP3A4—Daunorubicin—hematologic cancer	0.00648	0.0149	CbGbCtD
Raloxifene—CYP2C8—Etoposide—hematologic cancer	0.00612	0.0141	CbGbCtD
Raloxifene—CYP3A4—Cytarabine—hematologic cancer	0.00571	0.0132	CbGbCtD
Raloxifene—CYP3A4—Teniposide—hematologic cancer	0.00563	0.013	CbGbCtD
Raloxifene—CYP2B6—Doxorubicin—hematologic cancer	0.00551	0.0127	CbGbCtD
Raloxifene—CYP3A4—Ifosfamide—hematologic cancer	0.00519	0.012	CbGbCtD
Raloxifene—CYP2C8—Dexamethasone—hematologic cancer	0.00503	0.0116	CbGbCtD
Raloxifene—CYP3A4—Imatinib—hematologic cancer	0.00496	0.0114	CbGbCtD
Raloxifene—CYP3A4—Ruxolitinib—hematologic cancer	0.00467	0.0108	CbGbCtD
Raloxifene—CYP3A4—Nilotinib—hematologic cancer	0.00451	0.0104	CbGbCtD
Raloxifene—CYP3A4—Vinorelbine—hematologic cancer	0.00447	0.0103	CbGbCtD
Raloxifene—CYP3A4—Triamcinolone—hematologic cancer	0.00409	0.00943	CbGbCtD
Raloxifene—CYP3A4—Dasatinib—hematologic cancer	0.00399	0.00919	CbGbCtD
Raloxifene—CYP3A4—Mitoxantrone—hematologic cancer	0.00394	0.00908	CbGbCtD
Raloxifene—CYP3A4—Betamethasone—hematologic cancer	0.00351	0.00809	CbGbCtD
Raloxifene—CYP3A4—Prednisolone—hematologic cancer	0.00346	0.00798	CbGbCtD
Raloxifene—CYP3A4—Prednisone—hematologic cancer	0.00327	0.00754	CbGbCtD
Raloxifene—CYP3A4—Irinotecan—hematologic cancer	0.0031	0.00715	CbGbCtD
Raloxifene—CYP3A4—Vinblastine—hematologic cancer	0.00276	0.00635	CbGbCtD
Raloxifene—CYP3A4—Vincristine—hematologic cancer	0.00271	0.00625	CbGbCtD
Raloxifene—CYP3A4—Etoposide—hematologic cancer	0.00248	0.00572	CbGbCtD
Raloxifene—CYP3A4—Dexamethasone—hematologic cancer	0.00204	0.00471	CbGbCtD
Raloxifene—CYP3A4—Doxorubicin—hematologic cancer	0.00169	0.0039	CbGbCtD
Raloxifene—ESR2—hematopoietic system—hematologic cancer	0.00149	0.0256	CbGeAlD
Raloxifene—CYP19A1—hematopoietic system—hematologic cancer	0.00117	0.0201	CbGeAlD
Raloxifene—ESR2—gonad—hematologic cancer	0.00113	0.0194	CbGeAlD
Raloxifene—AOX1—gonad—hematologic cancer	0.00109	0.0187	CbGeAlD
Raloxifene—ESR1—hematopoietic system—hematologic cancer	0.00102	0.0175	CbGeAlD
Raloxifene—ESR2—blood—hematologic cancer	0.000987	0.0169	CbGeAlD
Raloxifene—CYP19A1—gonad—hematologic cancer	0.000892	0.0153	CbGeAlD
Raloxifene—ESR2—lung—hematologic cancer	0.000865	0.0148	CbGeAlD
Raloxifene—Flavoxate—PDE4B—hematologic cancer	0.000844	1	CrCbGaD
Raloxifene—CYP2C8—hematopoietic system—hematologic cancer	0.00084	0.0144	CbGeAlD
Raloxifene—AOX1—lung—hematologic cancer	0.000833	0.0143	CbGeAlD
Raloxifene—ESR2—testis—hematologic cancer	0.000816	0.014	CbGeAlD
Raloxifene—AOX1—testis—hematologic cancer	0.000786	0.0135	CbGeAlD
Raloxifene—CYP19A1—blood—hematologic cancer	0.000778	0.0133	CbGeAlD
Raloxifene—ESR1—gonad—hematologic cancer	0.000776	0.0133	CbGeAlD
Raloxifene—SIGMAR1—blood—hematologic cancer	0.000764	0.0131	CbGeAlD
Raloxifene—HTR2B—blood—hematologic cancer	0.000763	0.0131	CbGeAlD
Raloxifene—CYP2B6—hematopoietic system—hematologic cancer	0.000754	0.0129	CbGeAlD
Raloxifene—SIGMAR1—bone marrow—hematologic cancer	0.00074	0.0127	CbGeAlD
Raloxifene—ESR1—blood—hematologic cancer	0.000676	0.0116	CbGeAlD
Raloxifene—SIGMAR1—lung—hematologic cancer	0.00067	0.0115	CbGeAlD
Raloxifene—HTR2B—lung—hematologic cancer	0.000669	0.0115	CbGeAlD
Raloxifene—CYP19A1—testis—hematologic cancer	0.000643	0.011	CbGeAlD
Raloxifene—SIGMAR1—testis—hematologic cancer	0.000632	0.0108	CbGeAlD
Raloxifene—ESR1—lung—hematologic cancer	0.000592	0.0102	CbGeAlD
Raloxifene—ESR2—lymph node—hematologic cancer	0.000592	0.0102	CbGeAlD
Raloxifene—CYP2B6—gonad—hematologic cancer	0.000573	0.00983	CbGeAlD
Raloxifene—AOX1—lymph node—hematologic cancer	0.000569	0.00977	CbGeAlD
Raloxifene—CYP3A4—hematopoietic system—hematologic cancer	0.000569	0.00977	CbGeAlD
Raloxifene—ESR1—testis—hematologic cancer	0.000559	0.00959	CbGeAlD
Raloxifene—CYP2C8—blood—hematologic cancer	0.000557	0.00955	CbGeAlD
Raloxifene—CYP2B6—blood—hematologic cancer	0.000499	0.00857	CbGeAlD
Raloxifene—CYP19A1—lymph node—hematologic cancer	0.000466	0.008	CbGeAlD
Raloxifene—CYP2C8—testis—hematologic cancer	0.00046	0.0079	CbGeAlD
Raloxifene—SIGMAR1—lymph node—hematologic cancer	0.000458	0.00786	CbGeAlD
Raloxifene—HTR2B—lymph node—hematologic cancer	0.000457	0.00785	CbGeAlD
Raloxifene—EBP—Azacitidine—Pentostatin—hematologic cancer	0.000452	0.192	CbGdCrCtD
Raloxifene—CYP2B6—lung—hematologic cancer	0.000438	0.00751	CbGeAlD
Raloxifene—CYP2B6—testis—hematologic cancer	0.000413	0.00709	CbGeAlD
Raloxifene—ESR1—lymph node—hematologic cancer	0.000405	0.00695	CbGeAlD
Raloxifene—EBP—Azacitidine—Clofarabine—hematologic cancer	0.000403	0.171	CbGdCrCtD
Raloxifene—EBP—Azacitidine—Nelarabine—hematologic cancer	0.000379	0.161	CbGdCrCtD
Raloxifene—CYP3A4—blood—hematologic cancer	0.000377	0.00647	CbGeAlD
Raloxifene—EBP—Azacitidine—Fludarabine—hematologic cancer	0.000296	0.125	CbGdCrCtD
Raloxifene—EBP—Azacitidine—Cytarabine—hematologic cancer	0.000279	0.118	CbGdCrCtD
Raloxifene—EBP—Azacitidine—Gemcitabine—hematologic cancer	0.000279	0.118	CbGdCrCtD
Raloxifene—EBP—Azacitidine—Cladribine—hematologic cancer	0.000272	0.115	CbGdCrCtD
Raloxifene—Sinusitis—Epirubicin—hematologic cancer	4.36e-05	0.000219	CcSEcCtD
Raloxifene—Diarrhoea—Mitoxantrone—hematologic cancer	4.35e-05	0.000219	CcSEcCtD
Raloxifene—Diarrhoea—Irinotecan—hematologic cancer	4.35e-05	0.000219	CcSEcCtD
Raloxifene—Vomiting—Carmustine—hematologic cancer	4.35e-05	0.000219	CcSEcCtD
Raloxifene—Insomnia—Triamcinolone—hematologic cancer	4.34e-05	0.000218	CcSEcCtD
Raloxifene—Pneumonia—Doxorubicin—hematologic cancer	4.32e-05	0.000218	CcSEcCtD
Raloxifene—Gastrointestinal pain—Etoposide—hematologic cancer	4.32e-05	0.000218	CcSEcCtD
Raloxifene—Infection—Betamethasone—hematologic cancer	4.32e-05	0.000218	CcSEcCtD
Raloxifene—Infection—Dexamethasone—hematologic cancer	4.32e-05	0.000218	CcSEcCtD
Raloxifene—Dizziness—Vincristine—hematologic cancer	4.32e-05	0.000217	CcSEcCtD
Raloxifene—Rash—Carmustine—hematologic cancer	4.31e-05	0.000217	CcSEcCtD
Raloxifene—Dermatitis—Carmustine—hematologic cancer	4.31e-05	0.000217	CcSEcCtD
Raloxifene—Vomiting—Alitretinoin—hematologic cancer	4.31e-05	0.000217	CcSEcCtD
Raloxifene—Headache—Carmustine—hematologic cancer	4.28e-05	0.000216	CcSEcCtD
Raloxifene—Shock—Dexamethasone—hematologic cancer	4.28e-05	0.000215	CcSEcCtD
Raloxifene—Shock—Betamethasone—hematologic cancer	4.28e-05	0.000215	CcSEcCtD
Raloxifene—Rash—Alitretinoin—hematologic cancer	4.27e-05	0.000215	CcSEcCtD
Raloxifene—Nervous system disorder—Betamethasone—hematologic cancer	4.27e-05	0.000215	CcSEcCtD
Raloxifene—Nervous system disorder—Dexamethasone—hematologic cancer	4.27e-05	0.000215	CcSEcCtD
Raloxifene—Dermatitis—Alitretinoin—hematologic cancer	4.27e-05	0.000215	CcSEcCtD
Raloxifene—Thrombocytopenia—Dexamethasone—hematologic cancer	4.26e-05	0.000214	CcSEcCtD
Raloxifene—Thrombocytopenia—Betamethasone—hematologic cancer	4.26e-05	0.000214	CcSEcCtD
Raloxifene—Vomiting—Ifosfamide—hematologic cancer	4.26e-05	0.000214	CcSEcCtD
Raloxifene—Headache—Alitretinoin—hematologic cancer	4.24e-05	0.000214	CcSEcCtD
Raloxifene—Diarrhoea—Gemcitabine—hematologic cancer	4.24e-05	0.000213	CcSEcCtD
Raloxifene—Nausea—Thalidomide—hematologic cancer	4.23e-05	0.000213	CcSEcCtD
Raloxifene—Dyspepsia—Triamcinolone—hematologic cancer	4.22e-05	0.000212	CcSEcCtD
Raloxifene—Rash—Ifosfamide—hematologic cancer	4.22e-05	0.000212	CcSEcCtD
Raloxifene—Dermatitis—Ifosfamide—hematologic cancer	4.22e-05	0.000212	CcSEcCtD
Raloxifene—Hyperhidrosis—Dexamethasone—hematologic cancer	4.21e-05	0.000212	CcSEcCtD
Raloxifene—Hyperhidrosis—Betamethasone—hematologic cancer	4.21e-05	0.000212	CcSEcCtD
Raloxifene—Dizziness—Irinotecan—hematologic cancer	4.2e-05	0.000212	CcSEcCtD
Raloxifene—Rhinitis—Epirubicin—hematologic cancer	4.18e-05	0.000211	CcSEcCtD
Raloxifene—Abdominal pain—Etoposide—hematologic cancer	4.18e-05	0.00021	CcSEcCtD
Raloxifene—Body temperature increased—Etoposide—hematologic cancer	4.18e-05	0.00021	CcSEcCtD
Raloxifene—Conjunctivitis—Doxorubicin—hematologic cancer	4.18e-05	0.00021	CcSEcCtD
Raloxifene—Urinary tract infection—Doxorubicin—hematologic cancer	4.18e-05	0.00021	CcSEcCtD
Raloxifene—Vertigo—Prednisone—hematologic cancer	4.17e-05	0.00021	CcSEcCtD
Raloxifene—Syncope—Prednisone—hematologic cancer	4.16e-05	0.00021	CcSEcCtD
Raloxifene—Hypoaesthesia—Epirubicin—hematologic cancer	4.15e-05	0.000209	CcSEcCtD
Raloxifene—Vomiting—Vincristine—hematologic cancer	4.15e-05	0.000209	CcSEcCtD
Raloxifene—Pharyngitis—Epirubicin—hematologic cancer	4.14e-05	0.000208	CcSEcCtD
Raloxifene—Cardiac disorder—Methotrexate—hematologic cancer	4.14e-05	0.000208	CcSEcCtD
Raloxifene—Sweating—Doxorubicin—hematologic cancer	4.12e-05	0.000207	CcSEcCtD
Raloxifene—Urinary tract disorder—Epirubicin—hematologic cancer	4.12e-05	0.000207	CcSEcCtD
Raloxifene—Rash—Vincristine—hematologic cancer	4.12e-05	0.000207	CcSEcCtD
Raloxifene—Dermatitis—Vincristine—hematologic cancer	4.11e-05	0.000207	CcSEcCtD
Raloxifene—Oedema peripheral—Epirubicin—hematologic cancer	4.11e-05	0.000207	CcSEcCtD
Raloxifene—Pain—Triamcinolone—hematologic cancer	4.1e-05	0.000206	CcSEcCtD
Raloxifene—Connective tissue disorder—Epirubicin—hematologic cancer	4.1e-05	0.000206	CcSEcCtD
Raloxifene—Urethral disorder—Epirubicin—hematologic cancer	4.09e-05	0.000206	CcSEcCtD
Raloxifene—Headache—Vincristine—hematologic cancer	4.09e-05	0.000206	CcSEcCtD
Raloxifene—Loss of consciousness—Prednisone—hematologic cancer	4.08e-05	0.000205	CcSEcCtD
Raloxifene—Nausea—Carmustine—hematologic cancer	4.06e-05	0.000204	CcSEcCtD
Raloxifene—Angiopathy—Methotrexate—hematologic cancer	4.04e-05	0.000204	CcSEcCtD
Raloxifene—Vomiting—Irinotecan—hematologic cancer	4.04e-05	0.000203	CcSEcCtD
Raloxifene—Vomiting—Mitoxantrone—hematologic cancer	4.04e-05	0.000203	CcSEcCtD
Raloxifene—Sinusitis—Doxorubicin—hematologic cancer	4.03e-05	0.000203	CcSEcCtD
Raloxifene—Nausea—Alitretinoin—hematologic cancer	4.02e-05	0.000203	CcSEcCtD
Raloxifene—Rash—Mitoxantrone—hematologic cancer	4.01e-05	0.000202	CcSEcCtD
Raloxifene—Rash—Irinotecan—hematologic cancer	4.01e-05	0.000202	CcSEcCtD
Raloxifene—Dermatitis—Mitoxantrone—hematologic cancer	4e-05	0.000202	CcSEcCtD
Raloxifene—Dermatitis—Irinotecan—hematologic cancer	4e-05	0.000202	CcSEcCtD
Raloxifene—Headache—Mitoxantrone—hematologic cancer	3.98e-05	0.0002	CcSEcCtD
Raloxifene—Headache—Irinotecan—hematologic cancer	3.98e-05	0.0002	CcSEcCtD
Raloxifene—Nausea—Ifosfamide—hematologic cancer	3.98e-05	0.0002	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	3.96e-05	0.0002	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Betamethasone—hematologic cancer	3.96e-05	0.0002	CcSEcCtD
Raloxifene—Arthralgia—Prednisone—hematologic cancer	3.95e-05	0.000199	CcSEcCtD
Raloxifene—Myalgia—Prednisone—hematologic cancer	3.95e-05	0.000199	CcSEcCtD
Raloxifene—Diarrhoea—Cisplatin—hematologic cancer	3.95e-05	0.000199	CcSEcCtD
Raloxifene—Vomiting—Gemcitabine—hematologic cancer	3.94e-05	0.000198	CcSEcCtD
Raloxifene—Insomnia—Betamethasone—hematologic cancer	3.94e-05	0.000198	CcSEcCtD
Raloxifene—Insomnia—Dexamethasone—hematologic cancer	3.94e-05	0.000198	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	3.93e-05	0.000198	CcSEcCtD
Raloxifene—Rash—Gemcitabine—hematologic cancer	3.9e-05	0.000197	CcSEcCtD
Raloxifene—Dermatitis—Gemcitabine—hematologic cancer	3.9e-05	0.000196	CcSEcCtD
Raloxifene—Headache—Gemcitabine—hematologic cancer	3.88e-05	0.000195	CcSEcCtD
Raloxifene—Nausea—Vincristine—hematologic cancer	3.88e-05	0.000195	CcSEcCtD
Raloxifene—Flushing—Epirubicin—hematologic cancer	3.87e-05	0.000195	CcSEcCtD
Raloxifene—Cardiac disorder—Epirubicin—hematologic cancer	3.87e-05	0.000195	CcSEcCtD
Raloxifene—Rhinitis—Doxorubicin—hematologic cancer	3.87e-05	0.000195	CcSEcCtD
Raloxifene—Hypoaesthesia—Doxorubicin—hematologic cancer	3.84e-05	0.000193	CcSEcCtD
Raloxifene—Pharyngitis—Doxorubicin—hematologic cancer	3.83e-05	0.000193	CcSEcCtD
Raloxifene—Dyspepsia—Dexamethasone—hematologic cancer	3.83e-05	0.000193	CcSEcCtD
Raloxifene—Dyspepsia—Betamethasone—hematologic cancer	3.83e-05	0.000193	CcSEcCtD
Raloxifene—Urinary tract disorder—Doxorubicin—hematologic cancer	3.81e-05	0.000192	CcSEcCtD
Raloxifene—Oedema peripheral—Doxorubicin—hematologic cancer	3.8e-05	0.000191	CcSEcCtD
Raloxifene—Connective tissue disorder—Doxorubicin—hematologic cancer	3.79e-05	0.000191	CcSEcCtD
Raloxifene—Body temperature increased—Triamcinolone—hematologic cancer	3.79e-05	0.000191	CcSEcCtD
Raloxifene—Angiopathy—Epirubicin—hematologic cancer	3.78e-05	0.000191	CcSEcCtD
Raloxifene—Urethral disorder—Doxorubicin—hematologic cancer	3.78e-05	0.00019	CcSEcCtD
Raloxifene—Nausea—Mitoxantrone—hematologic cancer	3.78e-05	0.00019	CcSEcCtD
Raloxifene—Nausea—Irinotecan—hematologic cancer	3.78e-05	0.00019	CcSEcCtD
Raloxifene—Infection—Prednisone—hematologic cancer	3.76e-05	0.00019	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Betamethasone—hematologic cancer	3.76e-05	0.000189	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Dexamethasone—hematologic cancer	3.76e-05	0.000189	CcSEcCtD
Raloxifene—Shock—Prednisone—hematologic cancer	3.73e-05	0.000188	CcSEcCtD
Raloxifene—Pain—Betamethasone—hematologic cancer	3.72e-05	0.000187	CcSEcCtD
Raloxifene—Pain—Dexamethasone—hematologic cancer	3.72e-05	0.000187	CcSEcCtD
Raloxifene—Nervous system disorder—Prednisone—hematologic cancer	3.72e-05	0.000187	CcSEcCtD
Raloxifene—Skin disorder—Prednisone—hematologic cancer	3.68e-05	0.000185	CcSEcCtD
Raloxifene—Nausea—Gemcitabine—hematologic cancer	3.68e-05	0.000185	CcSEcCtD
Raloxifene—Vomiting—Cisplatin—hematologic cancer	3.67e-05	0.000185	CcSEcCtD
Raloxifene—Hyperhidrosis—Prednisone—hematologic cancer	3.66e-05	0.000184	CcSEcCtD
Raloxifene—Rash—Cisplatin—hematologic cancer	3.64e-05	0.000183	CcSEcCtD
Raloxifene—Dermatitis—Cisplatin—hematologic cancer	3.64e-05	0.000183	CcSEcCtD
Raloxifene—Diarrhoea—Etoposide—hematologic cancer	3.62e-05	0.000182	CcSEcCtD
Raloxifene—Cardiac disorder—Doxorubicin—hematologic cancer	3.58e-05	0.00018	CcSEcCtD
Raloxifene—Flushing—Doxorubicin—hematologic cancer	3.58e-05	0.00018	CcSEcCtD
Raloxifene—Flatulence—Epirubicin—hematologic cancer	3.58e-05	0.00018	CcSEcCtD
Raloxifene—Gastrointestinal pain—Dexamethasone—hematologic cancer	3.56e-05	0.000179	CcSEcCtD
Raloxifene—Gastrointestinal pain—Betamethasone—hematologic cancer	3.56e-05	0.000179	CcSEcCtD
Raloxifene—Angiopathy—Doxorubicin—hematologic cancer	3.5e-05	0.000176	CcSEcCtD
Raloxifene—Dizziness—Etoposide—hematologic cancer	3.5e-05	0.000176	CcSEcCtD
Raloxifene—Muscle spasms—Epirubicin—hematologic cancer	3.49e-05	0.000176	CcSEcCtD
Raloxifene—Vertigo—Methotrexate—hematologic cancer	3.49e-05	0.000175	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Prednisone—hematologic cancer	3.45e-05	0.000174	CcSEcCtD
Raloxifene—Dizziness—Prednisolone—hematologic cancer	3.45e-05	0.000174	CcSEcCtD
Raloxifene—Abdominal pain—Betamethasone—hematologic cancer	3.44e-05	0.000173	CcSEcCtD
Raloxifene—Body temperature increased—Dexamethasone—hematologic cancer	3.44e-05	0.000173	CcSEcCtD
Raloxifene—Abdominal pain—Dexamethasone—hematologic cancer	3.44e-05	0.000173	CcSEcCtD
Raloxifene—Body temperature increased—Betamethasone—hematologic cancer	3.44e-05	0.000173	CcSEcCtD
Raloxifene—Nausea—Cisplatin—hematologic cancer	3.43e-05	0.000173	CcSEcCtD
Raloxifene—Insomnia—Prednisone—hematologic cancer	3.43e-05	0.000173	CcSEcCtD
Raloxifene—Cough—Methotrexate—hematologic cancer	3.39e-05	0.00017	CcSEcCtD
Raloxifene—Vomiting—Etoposide—hematologic cancer	3.36e-05	0.000169	CcSEcCtD
Raloxifene—Dyspepsia—Prednisone—hematologic cancer	3.34e-05	0.000168	CcSEcCtD
Raloxifene—Rash—Etoposide—hematologic cancer	3.33e-05	0.000168	CcSEcCtD
Raloxifene—Dermatitis—Etoposide—hematologic cancer	3.33e-05	0.000168	CcSEcCtD
Raloxifene—Headache—Etoposide—hematologic cancer	3.31e-05	0.000167	CcSEcCtD
Raloxifene—Flatulence—Doxorubicin—hematologic cancer	3.31e-05	0.000167	CcSEcCtD
Raloxifene—Arthralgia—Methotrexate—hematologic cancer	3.3e-05	0.000166	CcSEcCtD
Raloxifene—Myalgia—Methotrexate—hematologic cancer	3.3e-05	0.000166	CcSEcCtD
Raloxifene—Chest pain—Methotrexate—hematologic cancer	3.3e-05	0.000166	CcSEcCtD
Raloxifene—Rash—Prednisolone—hematologic cancer	3.29e-05	0.000166	CcSEcCtD
Raloxifene—Dermatitis—Prednisolone—hematologic cancer	3.29e-05	0.000165	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	3.28e-05	0.000165	CcSEcCtD
Raloxifene—Headache—Prednisolone—hematologic cancer	3.27e-05	0.000164	CcSEcCtD
Raloxifene—Vertigo—Epirubicin—hematologic cancer	3.26e-05	0.000164	CcSEcCtD
Raloxifene—Syncope—Epirubicin—hematologic cancer	3.26e-05	0.000164	CcSEcCtD
Raloxifene—Muscle spasms—Doxorubicin—hematologic cancer	3.23e-05	0.000163	CcSEcCtD
Raloxifene—Loss of consciousness—Epirubicin—hematologic cancer	3.19e-05	0.000161	CcSEcCtD
Raloxifene—Dizziness—Triamcinolone—hematologic cancer	3.17e-05	0.00016	CcSEcCtD
Raloxifene—Cough—Epirubicin—hematologic cancer	3.17e-05	0.00016	CcSEcCtD
Raloxifene—Infection—Methotrexate—hematologic cancer	3.15e-05	0.000158	CcSEcCtD
Raloxifene—Nausea—Etoposide—hematologic cancer	3.14e-05	0.000158	CcSEcCtD
Raloxifene—Nervous system disorder—Methotrexate—hematologic cancer	3.11e-05	0.000156	CcSEcCtD
Raloxifene—Thrombocytopenia—Methotrexate—hematologic cancer	3.1e-05	0.000156	CcSEcCtD
Raloxifene—Gastrointestinal pain—Prednisone—hematologic cancer	3.1e-05	0.000156	CcSEcCtD
Raloxifene—Nausea—Prednisolone—hematologic cancer	3.1e-05	0.000156	CcSEcCtD
Raloxifene—Arthralgia—Epirubicin—hematologic cancer	3.09e-05	0.000156	CcSEcCtD
Raloxifene—Chest pain—Epirubicin—hematologic cancer	3.09e-05	0.000156	CcSEcCtD
Raloxifene—Myalgia—Epirubicin—hematologic cancer	3.09e-05	0.000156	CcSEcCtD
Raloxifene—Skin disorder—Methotrexate—hematologic cancer	3.08e-05	0.000155	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	3.07e-05	0.000155	CcSEcCtD
Raloxifene—Hyperhidrosis—Methotrexate—hematologic cancer	3.06e-05	0.000154	CcSEcCtD
Raloxifene—Vomiting—Triamcinolone—hematologic cancer	3.05e-05	0.000153	CcSEcCtD
Raloxifene—Rash—Triamcinolone—hematologic cancer	3.02e-05	0.000152	CcSEcCtD
Raloxifene—Dermatitis—Triamcinolone—hematologic cancer	3.02e-05	0.000152	CcSEcCtD
Raloxifene—Vertigo—Doxorubicin—hematologic cancer	3.02e-05	0.000152	CcSEcCtD
Raloxifene—Syncope—Doxorubicin—hematologic cancer	3.01e-05	0.000152	CcSEcCtD
Raloxifene—Headache—Triamcinolone—hematologic cancer	3e-05	0.000151	CcSEcCtD
Raloxifene—Abdominal pain—Prednisone—hematologic cancer	3e-05	0.000151	CcSEcCtD
Raloxifene—Body temperature increased—Prednisone—hematologic cancer	3e-05	0.000151	CcSEcCtD
Raloxifene—Diarrhoea—Betamethasone—hematologic cancer	2.98e-05	0.00015	CcSEcCtD
Raloxifene—Diarrhoea—Dexamethasone—hematologic cancer	2.98e-05	0.00015	CcSEcCtD
Raloxifene—Loss of consciousness—Doxorubicin—hematologic cancer	2.95e-05	0.000149	CcSEcCtD
Raloxifene—Infection—Epirubicin—hematologic cancer	2.94e-05	0.000148	CcSEcCtD
Raloxifene—Cough—Doxorubicin—hematologic cancer	2.93e-05	0.000148	CcSEcCtD
Raloxifene—Shock—Epirubicin—hematologic cancer	2.92e-05	0.000147	CcSEcCtD
Raloxifene—Nervous system disorder—Epirubicin—hematologic cancer	2.91e-05	0.000146	CcSEcCtD
Raloxifene—Thrombocytopenia—Epirubicin—hematologic cancer	2.9e-05	0.000146	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Methotrexate—hematologic cancer	2.89e-05	0.000145	CcSEcCtD
Raloxifene—Skin disorder—Epirubicin—hematologic cancer	2.88e-05	0.000145	CcSEcCtD
Raloxifene—Dizziness—Dexamethasone—hematologic cancer	2.88e-05	0.000145	CcSEcCtD
Raloxifene—Dizziness—Betamethasone—hematologic cancer	2.88e-05	0.000145	CcSEcCtD
Raloxifene—Hyperhidrosis—Epirubicin—hematologic cancer	2.87e-05	0.000144	CcSEcCtD
Raloxifene—Insomnia—Methotrexate—hematologic cancer	2.86e-05	0.000144	CcSEcCtD
Raloxifene—Arthralgia—Doxorubicin—hematologic cancer	2.86e-05	0.000144	CcSEcCtD
Raloxifene—Chest pain—Doxorubicin—hematologic cancer	2.86e-05	0.000144	CcSEcCtD
Raloxifene—Myalgia—Doxorubicin—hematologic cancer	2.86e-05	0.000144	CcSEcCtD
Raloxifene—Nausea—Triamcinolone—hematologic cancer	2.85e-05	0.000143	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	2.84e-05	0.000143	CcSEcCtD
Raloxifene—Dyspepsia—Methotrexate—hematologic cancer	2.79e-05	0.00014	CcSEcCtD
Raloxifene—Vomiting—Betamethasone—hematologic cancer	2.77e-05	0.000139	CcSEcCtD
Raloxifene—Vomiting—Dexamethasone—hematologic cancer	2.77e-05	0.000139	CcSEcCtD
Raloxifene—Rash—Dexamethasone—hematologic cancer	2.74e-05	0.000138	CcSEcCtD
Raloxifene—Rash—Betamethasone—hematologic cancer	2.74e-05	0.000138	CcSEcCtD
Raloxifene—Dermatitis—Dexamethasone—hematologic cancer	2.74e-05	0.000138	CcSEcCtD
Raloxifene—Dermatitis—Betamethasone—hematologic cancer	2.74e-05	0.000138	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Methotrexate—hematologic cancer	2.73e-05	0.000138	CcSEcCtD
Raloxifene—Headache—Dexamethasone—hematologic cancer	2.73e-05	0.000137	CcSEcCtD
Raloxifene—Headache—Betamethasone—hematologic cancer	2.73e-05	0.000137	CcSEcCtD
Raloxifene—Infection—Doxorubicin—hematologic cancer	2.72e-05	0.000137	CcSEcCtD
Raloxifene—Pain—Methotrexate—hematologic cancer	2.71e-05	0.000136	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Epirubicin—hematologic cancer	2.7e-05	0.000136	CcSEcCtD
Raloxifene—Shock—Doxorubicin—hematologic cancer	2.7e-05	0.000136	CcSEcCtD
Raloxifene—Nervous system disorder—Doxorubicin—hematologic cancer	2.69e-05	0.000135	CcSEcCtD
Raloxifene—Thrombocytopenia—Doxorubicin—hematologic cancer	2.69e-05	0.000135	CcSEcCtD
Raloxifene—Insomnia—Epirubicin—hematologic cancer	2.68e-05	0.000135	CcSEcCtD
Raloxifene—Skin disorder—Doxorubicin—hematologic cancer	2.66e-05	0.000134	CcSEcCtD
Raloxifene—Hyperhidrosis—Doxorubicin—hematologic cancer	2.65e-05	0.000133	CcSEcCtD
Raloxifene—Dyspepsia—Epirubicin—hematologic cancer	2.61e-05	0.000131	CcSEcCtD
Raloxifene—Diarrhoea—Prednisone—hematologic cancer	2.59e-05	0.000131	CcSEcCtD
Raloxifene—Gastrointestinal pain—Methotrexate—hematologic cancer	2.59e-05	0.00013	CcSEcCtD
Raloxifene—Nausea—Dexamethasone—hematologic cancer	2.58e-05	0.00013	CcSEcCtD
Raloxifene—Nausea—Betamethasone—hematologic cancer	2.58e-05	0.00013	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Epirubicin—hematologic cancer	2.56e-05	0.000129	CcSEcCtD
Raloxifene—Pain—Epirubicin—hematologic cancer	2.53e-05	0.000128	CcSEcCtD
Raloxifene—Dizziness—Prednisone—hematologic cancer	2.51e-05	0.000126	CcSEcCtD
Raloxifene—Abdominal pain—Methotrexate—hematologic cancer	2.5e-05	0.000126	CcSEcCtD
Raloxifene—Body temperature increased—Methotrexate—hematologic cancer	2.5e-05	0.000126	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	2.5e-05	0.000126	CcSEcCtD
Raloxifene—Insomnia—Doxorubicin—hematologic cancer	2.48e-05	0.000125	CcSEcCtD
Raloxifene—Gastrointestinal pain—Epirubicin—hematologic cancer	2.42e-05	0.000122	CcSEcCtD
Raloxifene—Dyspepsia—Doxorubicin—hematologic cancer	2.41e-05	0.000122	CcSEcCtD
Raloxifene—Vomiting—Prednisone—hematologic cancer	2.41e-05	0.000121	CcSEcCtD
Raloxifene—Rash—Prednisone—hematologic cancer	2.39e-05	0.00012	CcSEcCtD
Raloxifene—Dermatitis—Prednisone—hematologic cancer	2.39e-05	0.00012	CcSEcCtD
Raloxifene—Headache—Prednisone—hematologic cancer	2.37e-05	0.000119	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Doxorubicin—hematologic cancer	2.37e-05	0.000119	CcSEcCtD
Raloxifene—Pain—Doxorubicin—hematologic cancer	2.35e-05	0.000118	CcSEcCtD
Raloxifene—Body temperature increased—Epirubicin—hematologic cancer	2.34e-05	0.000118	CcSEcCtD
Raloxifene—Abdominal pain—Epirubicin—hematologic cancer	2.34e-05	0.000118	CcSEcCtD
Raloxifene—Nausea—Prednisone—hematologic cancer	2.25e-05	0.000113	CcSEcCtD
Raloxifene—Gastrointestinal pain—Doxorubicin—hematologic cancer	2.24e-05	0.000113	CcSEcCtD
Raloxifene—Abdominal pain—Doxorubicin—hematologic cancer	2.17e-05	0.000109	CcSEcCtD
Raloxifene—Body temperature increased—Doxorubicin—hematologic cancer	2.17e-05	0.000109	CcSEcCtD
Raloxifene—Diarrhoea—Methotrexate—hematologic cancer	2.17e-05	0.000109	CcSEcCtD
Raloxifene—Dizziness—Methotrexate—hematologic cancer	2.09e-05	0.000105	CcSEcCtD
Raloxifene—Diarrhoea—Epirubicin—hematologic cancer	2.03e-05	0.000102	CcSEcCtD
Raloxifene—Vomiting—Methotrexate—hematologic cancer	2.01e-05	0.000101	CcSEcCtD
Raloxifene—Rash—Methotrexate—hematologic cancer	2e-05	0.000101	CcSEcCtD
Raloxifene—Dermatitis—Methotrexate—hematologic cancer	2e-05	0.0001	CcSEcCtD
Raloxifene—Headache—Methotrexate—hematologic cancer	1.98e-05	9.99e-05	CcSEcCtD
Raloxifene—Dizziness—Epirubicin—hematologic cancer	1.96e-05	9.87e-05	CcSEcCtD
Raloxifene—Vomiting—Epirubicin—hematologic cancer	1.88e-05	9.49e-05	CcSEcCtD
Raloxifene—Nausea—Methotrexate—hematologic cancer	1.88e-05	9.47e-05	CcSEcCtD
Raloxifene—Diarrhoea—Doxorubicin—hematologic cancer	1.88e-05	9.44e-05	CcSEcCtD
Raloxifene—Rash—Epirubicin—hematologic cancer	1.87e-05	9.41e-05	CcSEcCtD
Raloxifene—Dermatitis—Epirubicin—hematologic cancer	1.87e-05	9.4e-05	CcSEcCtD
Raloxifene—Headache—Epirubicin—hematologic cancer	1.86e-05	9.35e-05	CcSEcCtD
Raloxifene—Dizziness—Doxorubicin—hematologic cancer	1.81e-05	9.13e-05	CcSEcCtD
Raloxifene—Nausea—Epirubicin—hematologic cancer	1.76e-05	8.86e-05	CcSEcCtD
Raloxifene—Vomiting—Doxorubicin—hematologic cancer	1.74e-05	8.78e-05	CcSEcCtD
Raloxifene—Rash—Doxorubicin—hematologic cancer	1.73e-05	8.7e-05	CcSEcCtD
Raloxifene—Dermatitis—Doxorubicin—hematologic cancer	1.73e-05	8.7e-05	CcSEcCtD
Raloxifene—Headache—Doxorubicin—hematologic cancer	1.72e-05	8.65e-05	CcSEcCtD
Raloxifene—Nausea—Doxorubicin—hematologic cancer	1.63e-05	8.2e-05	CcSEcCtD
Raloxifene—ESR1—Signaling Pathways—PDGFRB—hematologic cancer	4.83e-06	5.89e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—FGFR3—hematologic cancer	4.82e-06	5.88e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MAPK14—hematologic cancer	4.77e-06	5.82e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PTPN11—hematologic cancer	4.76e-06	5.81e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PDGFRA—hematologic cancer	4.76e-06	5.8e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PRKCG—hematologic cancer	4.74e-06	5.78e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—JAK1—hematologic cancer	4.74e-06	5.78e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CD44—hematologic cancer	4.71e-06	5.74e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—NQO1—hematologic cancer	4.71e-06	5.74e-05	CbGpPWpGaD
Raloxifene—AOX1—Disease—IL6—hematologic cancer	4.7e-06	5.74e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—ESR1—hematologic cancer	4.68e-06	5.71e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—MAPK3—hematologic cancer	4.64e-06	5.67e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—GSTP1—hematologic cancer	4.64e-06	5.66e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—FN1—hematologic cancer	4.63e-06	5.64e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CREB1—hematologic cancer	4.62e-06	5.63e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—HMMR—hematologic cancer	4.61e-06	5.62e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—IDH2—hematologic cancer	4.61e-06	5.62e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	4.61e-06	5.62e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—BAD—hematologic cancer	4.57e-06	5.58e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—NFKBIA—hematologic cancer	4.57e-06	5.58e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—CREBBP—hematologic cancer	4.57e-06	5.57e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—BRAF—hematologic cancer	4.56e-06	5.56e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—NOTCH1—hematologic cancer	4.53e-06	5.52e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CCL2—hematologic cancer	4.52e-06	5.51e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—IL6R—hematologic cancer	4.5e-06	5.49e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CREBBP—hematologic cancer	4.5e-06	5.49e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CYCS—hematologic cancer	4.45e-06	5.43e-05	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—PIK3CA—hematologic cancer	4.45e-06	5.43e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CD80—hematologic cancer	4.43e-06	5.41e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PIK3CG—hematologic cancer	4.43e-06	5.4e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—KIT—hematologic cancer	4.43e-06	5.4e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—NRAS—hematologic cancer	4.43e-06	5.4e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—IL2RA—hematologic cancer	4.43e-06	5.4e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—HSP90AA1—hematologic cancer	4.42e-06	5.4e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—ABCB1—hematologic cancer	4.39e-06	5.35e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TERT—hematologic cancer	4.38e-06	5.34e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PTPN11—hematologic cancer	4.35e-06	5.31e-05	CbGpPWpGaD
Raloxifene—AOX1—Disease—AKT1—hematologic cancer	4.34e-06	5.3e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ARNTL—hematologic cancer	4.33e-06	5.29e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PIK3CD—hematologic cancer	4.33e-06	5.28e-05	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—AKT1—hematologic cancer	4.29e-06	5.24e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MAP2K1—hematologic cancer	4.29e-06	5.24e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—ALB—hematologic cancer	4.27e-06	5.22e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PDGFB—hematologic cancer	4.27e-06	5.21e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PIK3CD—hematologic cancer	4.26e-06	5.2e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—NCOR1—hematologic cancer	4.26e-06	5.2e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—GSTM1—hematologic cancer	4.26e-06	5.2e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—MAPK3—hematologic cancer	4.24e-06	5.17e-05	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—PIK3CA—hematologic cancer	4.22e-06	5.15e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ACP5—hematologic cancer	4.22e-06	5.14e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CA9—hematologic cancer	4.22e-06	5.14e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CREB1—hematologic cancer	4.21e-06	5.14e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TSC2—hematologic cancer	4.18e-06	5.09e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—KRAS—hematologic cancer	4.17e-06	5.09e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—NCOR2—hematologic cancer	4.16e-06	5.08e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—BRAF—hematologic cancer	4.16e-06	5.08e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CCL2—hematologic cancer	4.12e-06	5.03e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—IL6R—hematologic cancer	4.11e-06	5.01e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CREBBP—hematologic cancer	4.1e-06	5.01e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PIK3R1—hematologic cancer	4.09e-06	4.99e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—FGF2—hematologic cancer	4.08e-06	4.98e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PIK3R1—hematologic cancer	4.03e-06	4.91e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—FGFR3—hematologic cancer	4.02e-06	4.9e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	3.98e-06	4.86e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MAPK14—hematologic cancer	3.98e-06	4.85e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—IDH1—hematologic cancer	3.96e-06	4.84e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—GSTP1—hematologic cancer	3.92e-06	4.79e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GSTO1—hematologic cancer	3.92e-06	4.78e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ABCC3—hematologic cancer	3.92e-06	4.78e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—TXN—hematologic cancer	3.92e-06	4.78e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MAP2K1—hematologic cancer	3.92e-06	4.78e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—JAK2—hematologic cancer	3.91e-06	4.77e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PIK3CD—hematologic cancer	3.89e-06	4.75e-05	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—PIK3CA—hematologic cancer	3.85e-06	4.7e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—FN1—hematologic cancer	3.85e-06	4.7e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—SPHK1—hematologic cancer	3.84e-06	4.68e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—PIK3CA—hematologic cancer	3.83e-06	4.68e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MDM2—hematologic cancer	3.82e-06	4.66e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—KRAS—hematologic cancer	3.81e-06	4.65e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—NFKBIA—hematologic cancer	3.81e-06	4.65e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—BAD—hematologic cancer	3.81e-06	4.65e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	3.8e-06	4.63e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PIK3CB—hematologic cancer	3.77e-06	4.61e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—NOTCH1—hematologic cancer	3.77e-06	4.6e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—MTHFR—hematologic cancer	3.77e-06	4.59e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—FGF2—hematologic cancer	3.73e-06	4.55e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MTOR—hematologic cancer	3.72e-06	4.53e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PIK3CB—hematologic cancer	3.72e-06	4.53e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—ABCB1—hematologic cancer	3.72e-06	4.53e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CD80—hematologic cancer	3.69e-06	4.51e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PIK3CG—hematologic cancer	3.69e-06	4.5e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—KIT—hematologic cancer	3.69e-06	4.5e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—UGT1A1—hematologic cancer	3.69e-06	4.5e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PIK3R1—hematologic cancer	3.67e-06	4.48e-05	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—AKT1—hematologic cancer	3.63e-06	4.43e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PTPN11—hematologic cancer	3.62e-06	4.42e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—GSTM1—hematologic cancer	3.61e-06	4.4e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—NCOR1—hematologic cancer	3.61e-06	4.4e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CRABP1—hematologic cancer	3.59e-06	4.37e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—SLC22A1—hematologic cancer	3.59e-06	4.37e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—JAK2—hematologic cancer	3.57e-06	4.36e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—HRAS—hematologic cancer	3.55e-06	4.33e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CREB1—hematologic cancer	3.51e-06	4.28e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—PIK3CA—hematologic cancer	3.5e-06	4.27e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ALOX5—hematologic cancer	3.49e-06	4.26e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CDKN1B—hematologic cancer	3.49e-06	4.25e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MDM2—hematologic cancer	3.49e-06	4.25e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—BRAF—hematologic cancer	3.47e-06	4.23e-05	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—AKT1—hematologic cancer	3.45e-06	4.21e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CCL2—hematologic cancer	3.43e-06	4.19e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—IL6R—hematologic cancer	3.42e-06	4.18e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CREBBP—hematologic cancer	3.42e-06	4.17e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CASP3—hematologic cancer	3.42e-06	4.17e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—IL2—hematologic cancer	3.41e-06	4.16e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—IL6—hematologic cancer	3.4e-06	4.14e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MTOR—hematologic cancer	3.39e-06	4.14e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PIK3CB—hematologic cancer	3.39e-06	4.14e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—NUP98—hematologic cancer	3.38e-06	4.13e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CCND1—hematologic cancer	3.33e-06	4.06e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—JUN—hematologic cancer	3.32e-06	4.05e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ADCY7—hematologic cancer	3.28e-06	4.01e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—NCOA3—hematologic cancer	3.28e-06	4.01e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MAP2K1—hematologic cancer	3.26e-06	3.98e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—NUP214—hematologic cancer	3.26e-06	3.98e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PTEN—hematologic cancer	3.26e-06	3.98e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PIK3CD—hematologic cancer	3.24e-06	3.95e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—HRAS—hematologic cancer	3.24e-06	3.95e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CDKN1A—hematologic cancer	3.22e-06	3.93e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PTEN—hematologic cancer	3.21e-06	3.92e-05	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—MAPK3—hematologic cancer	3.21e-06	3.91e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ABCG2—hematologic cancer	3.2e-06	3.9e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—MTR—hematologic cancer	3.2e-06	3.9e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—MTHFR—hematologic cancer	3.19e-06	3.89e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CDKN1B—hematologic cancer	3.18e-06	3.88e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PIK3CG—hematologic cancer	3.16e-06	3.86e-05	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—AKT1—hematologic cancer	3.15e-06	3.84e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MAPK8—hematologic cancer	3.14e-06	3.83e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ENO2—hematologic cancer	3.13e-06	3.82e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—AKT1—hematologic cancer	3.13e-06	3.82e-05	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—MYC—hematologic cancer	3.12e-06	3.81e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CASP3—hematologic cancer	3.12e-06	3.81e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—IL2—hematologic cancer	3.11e-06	3.8e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—EP300—hematologic cancer	3.11e-06	3.79e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—FGF2—hematologic cancer	3.1e-06	3.79e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—IL6—hematologic cancer	3.1e-06	3.78e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—EP300—hematologic cancer	3.06e-06	3.74e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PIK3R1—hematologic cancer	3.06e-06	3.73e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GSTT1—hematologic cancer	3.04e-06	3.71e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CCND1—hematologic cancer	3.04e-06	3.7e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—JUN—hematologic cancer	3.03e-06	3.7e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—SRC—hematologic cancer	2.98e-06	3.63e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—JAK2—hematologic cancer	2.97e-06	3.63e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—SDC1—hematologic cancer	2.97e-06	3.62e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CDKN1A—hematologic cancer	2.94e-06	3.58e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—CREBBP—hematologic cancer	2.93e-06	3.58e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PTEN—hematologic cancer	2.93e-06	3.58e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MDM2—hematologic cancer	2.9e-06	3.54e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—VEGFA—hematologic cancer	2.9e-06	3.54e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—STAT3—hematologic cancer	2.87e-06	3.5e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MAPK8—hematologic cancer	2.87e-06	3.5e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—NRAS—hematologic cancer	2.86e-06	3.5e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—AKT1—hematologic cancer	2.86e-06	3.49e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PIK3CB—hematologic cancer	2.83e-06	3.45e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MTOR—hematologic cancer	2.83e-06	3.45e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	2.81e-06	3.43e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—EP300—hematologic cancer	2.8e-06	3.41e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PIK3CD—hematologic cancer	2.78e-06	3.39e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—ALB—hematologic cancer	2.75e-06	3.35e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MAPK3—hematologic cancer	2.74e-06	3.35e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—SRC—hematologic cancer	2.72e-06	3.32e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PIK3CG—hematologic cancer	2.68e-06	3.27e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MYC—hematologic cancer	2.67e-06	3.26e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—TGFB1—hematologic cancer	2.66e-06	3.25e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CDKN1B—hematologic cancer	2.65e-06	3.24e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—VEGFA—hematologic cancer	2.65e-06	3.23e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PIK3R1—hematologic cancer	2.63e-06	3.2e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—STAT3—hematologic cancer	2.62e-06	3.2e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—NRAS—hematologic cancer	2.61e-06	3.19e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CASP3—hematologic cancer	2.6e-06	3.17e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—IL2—hematologic cancer	2.59e-06	3.17e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CCND1—hematologic cancer	2.53e-06	3.09e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—NQO1—hematologic cancer	2.53e-06	3.08e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CD44—hematologic cancer	2.53e-06	3.08e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—JUN—hematologic cancer	2.52e-06	3.08e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MAPK3—hematologic cancer	2.5e-06	3.06e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CREBBP—hematologic cancer	2.48e-06	3.03e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—KRAS—hematologic cancer	2.47e-06	3.01e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CDKN1A—hematologic cancer	2.45e-06	2.99e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PTEN—hematologic cancer	2.44e-06	2.98e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MYC—hematologic cancer	2.44e-06	2.97e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—TGFB1—hematologic cancer	2.43e-06	2.96e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PIK3CB—hematologic cancer	2.42e-06	2.96e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CYCS—hematologic cancer	2.39e-06	2.92e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MAPK8—hematologic cancer	2.39e-06	2.91e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	2.37e-06	2.9e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PIK3CD—hematologic cancer	2.35e-06	2.87e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—EP300—hematologic cancer	2.33e-06	2.84e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—ALB—hematologic cancer	2.32e-06	2.84e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PIK3CA—hematologic cancer	2.3e-06	2.81e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PIK3CA—hematologic cancer	2.27e-06	2.76e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—SRC—hematologic cancer	2.26e-06	2.76e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—KRAS—hematologic cancer	2.25e-06	2.75e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PIK3R1—hematologic cancer	2.22e-06	2.71e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—VEGFA—hematologic cancer	2.21e-06	2.69e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—TP53—hematologic cancer	2.19e-06	2.67e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—STAT3—hematologic cancer	2.18e-06	2.66e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—NRAS—hematologic cancer	2.18e-06	2.66e-05	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—AKT1—hematologic cancer	2.16e-06	2.64e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GSTP1—hematologic cancer	2.11e-06	2.57e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—HRAS—hematologic cancer	2.1e-06	2.56e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PTEN—hematologic cancer	2.09e-06	2.56e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MAPK3—hematologic cancer	2.09e-06	2.55e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PIK3CA—hematologic cancer	2.07e-06	2.52e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PIK3CB—hematologic cancer	2.05e-06	2.5e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MYC—hematologic cancer	2.03e-06	2.48e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TGFB1—hematologic cancer	2.02e-06	2.47e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—IL6—hematologic cancer	2.01e-06	2.45e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—TP53—hematologic cancer	2e-06	2.44e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—EP300—hematologic cancer	2e-06	2.44e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ABCB1—hematologic cancer	1.99e-06	2.43e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GSTM1—hematologic cancer	1.94e-06	2.36e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—NCOR1—hematologic cancer	1.94e-06	2.36e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—HRAS—hematologic cancer	1.91e-06	2.33e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—AKT1—hematologic cancer	1.88e-06	2.29e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—KRAS—hematologic cancer	1.87e-06	2.29e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—AKT1—hematologic cancer	1.85e-06	2.26e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—IL6—hematologic cancer	1.83e-06	2.23e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PTEN—hematologic cancer	1.77e-06	2.16e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PIK3CA—hematologic cancer	1.72e-06	2.1e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—MTHFR—hematologic cancer	1.71e-06	2.09e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—EP300—hematologic cancer	1.69e-06	2.06e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—AKT1—hematologic cancer	1.69e-06	2.06e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TP53—hematologic cancer	1.67e-06	2.03e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—HRAS—hematologic cancer	1.59e-06	1.94e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—IL6—hematologic cancer	1.53e-06	1.86e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PIK3CA—hematologic cancer	1.48e-06	1.8e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PIK3CG—hematologic cancer	1.44e-06	1.75e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—AKT1—hematologic cancer	1.41e-06	1.72e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CREBBP—hematologic cancer	1.33e-06	1.63e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PIK3CD—hematologic cancer	1.26e-06	1.54e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PIK3CA—hematologic cancer	1.25e-06	1.53e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ALB—hematologic cancer	1.25e-06	1.52e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—AKT1—hematologic cancer	1.21e-06	1.47e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PIK3R1—hematologic cancer	1.19e-06	1.46e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.1e-06	1.34e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—AKT1—hematologic cancer	1.02e-06	1.25e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PTEN—hematologic cancer	9.52e-07	1.16e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—EP300—hematologic cancer	9.08e-07	1.11e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PIK3CA—hematologic cancer	6.71e-07	8.19e-06	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—AKT1—hematologic cancer	5.49e-07	6.69e-06	CbGpPWpGaD
